LATEST
Israeli Medics Face ICC Complaint Over Torture of Gaza DetaineesGaza’s Year of ‘Ceasefire’: Children Killed, Disease Spreading and Families Facing Another Winter in TentsInternational Football’s D-Day: A Prime Opportunity to Overthrow the Hegemony of Zurich‘We Are Dead in Gaza’: Three Years of Destruction, Displacement and the Struggle to SurviveIsrael Is Tearing Itself Apart Warn Former US Officials as Gaza War Deepens CrisisFormer CIA Analyst Says US Soldiers’ Parents Told Him Nuclear Defence Units Are Deploying to KuwaitArchive Genocide Releases Gaza Evidence Map on Eve of 7 October AnniversaryMCR EXEC Warns Uber Drivers: A Premium EV Does Not Automatically Create a Chauffeur BusinessGaza’s Returned Dead: Organ-Removal Allegations Remain Unresolved as UN Calls for InvestigatorsPope Mourns Christian Mother and Daughter Killed by Israel After Leaving Church Shelter in GazaIsraeli Medics Face ICC Complaint Over Torture of Gaza DetaineesGaza’s Year of ‘Ceasefire’: Children Killed, Disease Spreading and Families Facing Another Winter in TentsInternational Football’s D-Day: A Prime Opportunity to Overthrow the Hegemony of Zurich‘We Are Dead in Gaza’: Three Years of Destruction, Displacement and the Struggle to SurviveIsrael Is Tearing Itself Apart Warn Former US Officials as Gaza War Deepens CrisisFormer CIA Analyst Says US Soldiers’ Parents Told Him Nuclear Defence Units Are Deploying to KuwaitArchive Genocide Releases Gaza Evidence Map on Eve of 7 October AnniversaryMCR EXEC Warns Uber Drivers: A Premium EV Does Not Automatically Create a Chauffeur BusinessGaza’s Returned Dead: Organ-Removal Allegations Remain Unresolved as UN Calls for InvestigatorsPope Mourns Christian Mother and Daughter Killed by Israel After Leaving Church Shelter in Gaza
Business

ProMIS Announces Completion of Continuance

Richard Powell  1 min read
ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN) (“ProMIS” or the “Corporation”) is pleased to announce that it has completed its continuance (the “Continuance”) from the Canada Business Corporations Act into the Province of Ontario under the Business Corporations Act (Ontario) as of July 13, 2023. The Continuance was approved by the Corporation’s shareholders with a 97.7% majority via a special resolution at the Corporation’s Annual Meeting of Shareholders held on June 29, 2023. The shift will facilitate internal management functions, and is not envisioned to impact operations. The Company continues to operate with its headquarters in Toronto as well as its research laboratories, under the direction of Chief Scientific Officer Dr. Neil Cashman, in British Columbia and its US office in Cambridge, MA.
  No action will be required by existing shareholders with respect to the Continuance.  

ProMIS Neurosciences Inc. is a development stage biotechnology corporation focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Multiple system atrophy (MSA). The Corporation’s proprietary target discovery engine is based on the use of two complementary techniques. The Corporation applies its thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Corporation is developing novel antibody therapeutics for AD, ALS and MSA.  ProMIS is headquartered in Toronto, Ontario, Canada with offices in Cambridge, Massachusetts, U.S.A. ProMIS is listed on the TSX under symbol PMN, and on the NASDAQ under the symbol PMN.

Related articles

Top